Business
Easton Pharmaceuticals Signs Letter Of Intent to Acquire Major Vaporizer and e-Liquids Manufacturer iBliss Inc.
Easton Pharmaceuticals Signs Letter Of Intent to Acquire Major Vaporizer and e-Liquids Manufacturer iBliss Inc..
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Signs Letter Of Intent to Acquire Major Vaporizer and e-Liquids Manufacturer iBliss Inc.\n \n \nEaston Pharmaceuticals Signs Letter Of Intent to Acquire Major Vaporizer and e-Liquids Manufacturer iBliss Inc.\n\niBliss's Current Sales Are In the Millions Of Dollars and Are Projected To Quickly Reach and Surpass $15,000,000 in Sales With Healthy Profit Margins in Excess of 40%\n\n \n TORONTO, ON--(Marketwired - Jan 23, 2017) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) Announces that it has signed a letter of intent to acquire 100% of revenue producing vaporizer manufacturer iBliss Inc., of Toronto, Ontario, Canada. \n iBliss Inc. is a tremendously fast growing vaporizer and e-liquids manufacturing company with surging international sales projected to conservatively reach and surpass $15,000,000 per year fairly quickly. iBliss currently generates several millions of dollars in sales with healthy margins in excess of 40%. iBliss has had tremendous growth over the past 3 years of being in business which includes sales throughout North America and recently adding several international markets in Europe, the Middle East and Russia which has it on track to reach $15,000,000 in sales. iBliss possesses in house manufacturing of its own line of e-liquids products in a certified and regulated laboratory. iBliss's sales continue to grow with demand for Vaporizer's and e-liquids surging internationally. The company also intends on launching consumer health related products through its liquids for use in vaporizers, which will also result in substantial growth. \n \"We are very excited to be entering into this Agreement with Easton. With the support of Easton's management, we will be able to continue our success and rapidly expand our sales internationally and launch our consumer health products through our e-liquids,\" stated iBliss President, Hung Tran.\n The iBliss acquisition is intended to have iBliss operate as a wholly owned subsidiary of Easton and will be separate from Easton's other business segments such it's woman's diagnostics, treatment and natural health products where Easton recently executed a distribution agreement with multi-national pharmaceutical company Gedeon Richter and its Mexican subsidiary company Gedeon Richter Mexico S.A.P.I. de C.V. for Easton / BMV Medica's Gynofit product....